LifeMD PE Ratio 2011-2024 | LFMD
Current and historical p/e ratio for LifeMD (LFMD) from 2011 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. LifeMD PE ratio as of November 05, 2024 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
LifeMD PE Ratio Historical Data | |||
---|---|---|---|
Date | Stock Price | TTM Net EPS | PE Ratio |
2024-11-05 | 4.46 | 0.00 | |
2024-06-30 | 6.86 | $-0.70 | 0.00 |
2024-03-31 | 10.28 | $-0.74 | 0.00 |
2023-12-31 | 8.29 | $-0.70 | 0.00 |
2023-09-30 | 6.25 | $-0.98 | 0.00 |
2023-06-30 | 4.35 | $-1.04 | 0.00 |
2023-03-31 | 1.70 | $-1.26 | 0.00 |
2022-12-31 | 1.94 | $-1.57 | 0.00 |
2022-09-30 | 1.97 | $-1.79 | 0.00 |
2022-06-30 | 2.04 | $-2.07 | 0.00 |
2022-03-31 | 3.53 | $-2.26 | 0.00 |
2021-12-31 | 3.87 | $-2.27 | 0.00 |
2021-09-30 | 6.21 | $-4.21 | 0.00 |
2021-06-30 | 11.78 | $-5.32 | 0.00 |
2021-03-31 | 15.82 | $-4.98 | 0.00 |
2020-12-31 | 6.53 | $-4.76 | 0.00 |
Sector | Industry | Market Cap | Revenue |
---|---|---|---|
Medical | Medical Services | $0.192B | $0.153B |
LifeMD Inc. is a telehealth company. It offers a full portfolio of direct-to-patient products and services. The company combines virtual medical treatment with prescription medications and unique over-the-counter products. Its network of licensed physicians offers telemedicine services and direct-to-consumer pharmacy to consumers. LifeMD Inc., formerly known as Conversion Labs, is based in NEW YORK. |
Stock Name | Country | Market Cap | PE Ratio |
---|---|---|---|
Elevance Health (ELV) | United States | $96.890B | 12.02 |
Cencora (COR) | United States | $46.107B | 17.62 |
DiDi Global (DIDIY) | China | $23.233B | 0.00 |
ICON (ICLR) | Ireland | $18.679B | 16.64 |
Revvity (RVTY) | United States | $15.535B | 26.63 |
Avantor (AVTR) | United States | $15.498B | 23.24 |
Natera (NTRA) | United States | $15.385B | 0.00 |
Viatris (VTRS) | United States | $13.858B | 4.22 |
BioMerieux (BMXMF) | France | $13.601B | 0.00 |
Solventum (SOLV) | United States | $12.636B | 0.00 |
CochLear (CHEOY) | Australia | $12.565B | 0.00 |
Medpace Holdings (MEDP) | United States | $10.202B | 28.74 |
Charles River Laboratories (CRL) | United States | $9.742B | 18.41 |
Sonic Healthcare (SKHHY) | Australia | $8.273B | 0.00 |
HealthEquity (HQY) | United States | $7.792B | 42.29 |
Doximity (DOCS) | United States | $7.787B | 49.34 |
Bausch + Lomb (BLCO) | Canada | $6.975B | 32.47 |
Life Times (LTH) | United States | $4.762B | 31.52 |
PACS (PACS) | United States | $4.502B | 0.00 |
Sotera Health (SHC) | United States | $4.367B | 23.36 |
Organon (OGN) | United States | $4.239B | 4.28 |
Surgery Partners (SGRY) | United States | $3.778B | 41.86 |
BrightSpring Health Services (BTSG) | United States | $3.070B | 65.30 |
Ardent Health Partners (ARDT) | United States | $2.577B | 0.00 |
Alignment Healthcare (ALHC) | United States | $2.546B | 0.00 |
Concentras Parent (CON) | United States | $2.480B | 0.00 |
Premier (PINC) | United States | $2.271B | 11.34 |
GoodRx Holdings (GDRX) | United States | $2.254B | 84.86 |
GeneDx Holdings (WGS) | United States | $2.057B | 0.00 |
Ryman Healthcare (RYHTY) | New Zealand | $2.036B | 0.00 |
Teladoc Health (TDOC) | United States | $1.575B | 0.00 |
AMN Healthcare Services Inc (AMN) | United States | $1.507B | 7.57 |
Progyny (PGNY) | United States | $1.425B | 25.06 |
Establishment Labs Holdings (ESTA) | $1.338B | 0.00 | |
Pediatrix Medical (MD) | United States | $1.319B | 12.91 |
CareDx (CDNA) | United States | $1.228B | 0.00 |
Agilon Health (AGL) | United States | $1.123B | 0.00 |
Embecta (EMBC) | United States | $0.864B | 5.76 |
InnovAge Holding (INNV) | United States | $0.822B | 0.00 |
QDM (QDMI) | Hong Kong, SAR China | $0.790B | 20.69 |
SBC Medicals (SBC) | United States | $0.722B | 0.00 |
Auna S.A (AUNA) | Luxembourg | $0.488B | 0.00 |
Sonida Senior Living (SNDA) | United States | $0.483B | 0.00 |
Enhabit (EHAB) | United States | $0.382B | 33.04 |
DocGo (DCGO) | United States | $0.355B | 13.35 |
COMPASS Pathways (CMPS) | United Kingdom | $0.309B | 0.00 |
Sera Prognostics (SERA) | United States | $0.255B | 0.00 |
ModivCare (MODV) | United States | $0.232B | 7.37 |
Beauty Health (SKIN) | United States | $0.211B | 0.00 |
Biodesix (BDSX) | United States | $0.195B | 0.00 |
Ascend Wellness Holdings (AAWH) | United States | $0.178B | 0.00 |
MultiPlan (MPLN) | United States | $0.136B | 0.00 |
Nutex Health (NUTX) | United States | $0.127B | 0.00 |
So-Young (SY) | China | $0.092B | 22.35 |
Harvard Apparatus Regenerative Technology (HRGN) | United States | $0.059B | 0.00 |
Singular Genomics Systems (OMIC) | United States | $0.057B | 0.00 |
OncoCyte (OCX) | United States | $0.049B | 0.00 |
NeueHealth (NEUE) | United States | $0.041B | 1.63 |
Co-Diagnostics (CODX) | United States | $0.039B | 0.00 |
IceCure Medical (ICCM) | Israel | $0.036B | 0.00 |
NeuroOne Medical Technologies (NMTC) | United States | $0.027B | 0.00 |
Pheton Holdings (PTHL) | China | $0.027B | 0.00 |
Oncology Institute (TOI) | United States | $0.021B | 0.00 |
SeaStar Medical Holding (ICU) | United States | $0.012B | 0.00 |
XWELL (XWEL) | United States | $0.009B | 0.00 |
Intelligent Bio Solutions (INBS) | United States | $0.007B | 0.00 |
BioNexus Gene Lab (BGLC) | $0.007B | 0.00 | |
KindlyMD (KDLY) | United States | $0.005B | 0.00 |
ISpecimen (ISPC) | United States | $0.004B | 0.00 |
NewGenIvf Group (NIVF) | Thailand | $0.003B | 0.00 |
Aclarion (ACON) | United States | $0.002B | 0.00 |
Cano Health (CANOQ) | United States | $0.001B | 0.00 |